FOLFOX6
Sponsors
William Sikov MD, Barbara Ann Karmanos Cancer Institute, European Organisation for Research and Treatment of Cancer - EORTC, Fudan University, SCRI Development Innovations, LLC
Conditions
BevacizimabCancer of ColonCancer of PancreasColon CancerColon CarcinomaColorectal CancerColorectal Cancer MetastaticEsophageal Squamous Cell Carcinoma
Phase 1
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
CompletedNCT01420874
Start: 2011-08-17End: 2020-10-19Updated: 2023-05-06
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
Not yet recruitingNCT07500298
Start: 2026-09-03End: 2032-12-27Target: 41Updated: 2026-03-30
Phase 2
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
CompletedNCT01363843
Start: 2010-05-31End: 2013-01-31Updated: 2020-06-11
Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases
TerminatedNCT01508000
Start: 2013-06-30End: 2016-09-30Updated: 2016-10-12
Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
CompletedNCT01605305
Start: 2008-09-30End: 2012-01-31Updated: 2012-05-24
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
CompletedNCT01749956
Start: 2013-01-31End: 2015-09-30Updated: 2017-02-07
Chemoradiation or Brachytherapy for Rectal Cancer
CompletedNCT02017704
Start: 2014-06-12End: 2023-01-31Updated: 2023-10-17
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
CompletedNCT02243358
Start: 2014-02-28End: 2020-01-14Updated: 2023-10-27